Pharmacological treatment for heart failure: a view from the brain.
Systolic heart failure is a feed-forward phenomenon with devastating consequences. Impaired cardiac function is the initiating event, but central nervous system mechanisms activated by persistent altered neural and humoral signals from the periphery play an important sustaining role. Animals with experimentally induced heart failure have neurochemical abnormalities in the brain that, when manipulated, profoundly affect sympathetic drive, volume regulation, and cardiac remodeling--critical determinants of outcome. This brief review explores recent studies that provide a strong rationale for the development of pharmaceutical agents that target central nervous system abnormalities in heart failure.
Felder
R B
RB
Medical Service, Department of Veterans Affairs Medical Center, Iowa City, Iowa, USA. robert-felder@uiowa.edu
Yu
Y
Y
Zhang
Z-H
ZH
Wei
S-G
SG
D000450:Aldosterone / Q000378:metabolism; D000809:Angiotensins / Q000187:drug effects / Q000378:metabolism; D000818:Animals; D001812:Blood-Brain Barrier; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology*; D002317:Cardiovascular Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D002450:Cell Communication; D016207:Cytokines / Q000378:metabolism; D004337:Drug Carriers; D015195:Drug Design; D054143:Heart Failure, Systolic / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D006801:Humans; D007249:Inflammation / Q000378:metabolism; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000503:physiopathology*
D000809:Angiotensins; D002317:Cardiovascular Agents; D016207:Cytokines; D004337:Drug Carriers; D000450:Aldosterone